GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Return-on-Tangible-Equity

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Return-on-Tangible-Equity : 52.13% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. China Resourcesnjiu Medical & Pharmaceutical Co's annualized net income for the quarter that ended in Mar. 2024 was ¥5,455 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥10,464 Mil. Therefore, China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 52.13%.

The historical rank and industry rank for China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:000999' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 22.29   Med: 28.91   Max: 33.44
Current: 32.14

During the past 13 years, China Resourcesnjiu Medical & Pharmaceutical Co's highest Return-on-Tangible-Equity was 33.44%. The lowest was 22.29%. And the median was 28.91%.

SZSE:000999's Return-on-Tangible-Equity is ranked better than
89.42% of 945 companies
in the Drug Manufacturers industry
Industry Median: 6.72 vs SZSE:000999: 32.14

China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Equity Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Equity Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.44 22.29 26.29 25.96 28.49

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.07 33.07 23.52 19.00 52.13

Competitive Comparison of China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity falls into.



China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Equity Calculation

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2852.932/( (10264.883+9764.961 )/ 2 )
=2852.932/10014.922
=28.49 %

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=5455.304/( (9764.961+11162.891)/ 2 )
=5455.304/10463.926
=52.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines